Okayama University Medical Research Updates (OU-MRU) 2018.09 Vol.58

Source: Okayama University (JAPAN), Public Relations and Information Strategy

For immediate release: 25 September 2018

Okayama University research: Insights into mechanisms governing the resistance to the anti-cancer medication cetuximab

(Okayama, 25 September) Okayama University researchers report in *Biochemical and Biophysical Research Communications* that the anti-cancer drug cetuximab is released with vesicles from cancer cells, findings that may enable the development of strategies to improve the effectiveness of cetuximab for treating head and neck cancer.

Head and neck squamous cell carcinoma (HNSCC) is a type of cancer derived from specific kinds of cells: squamous cells in the mouth, nose, and throat. An important signaling pathway that promotes the survival and growth of these cancer cells is initiated by the protein EGF when it binds to its receptor EGFR. Research has shown that risk factors for HNSCC such as cigarette smoking, can increase the secretion of EGF and in turn simulate this pathway.

Cetuximab is a monoclonal antibody acting against EGFR that is widely used to treat HNSCC. This means that cetuximab binds to EGFR with greater affinity than EGF but will not let the subsequent pathway to function. However, recently, the emergence of resistance to cetuximab has been discovered but its mechanism is not clear.

The prime feature of oral squamous cell carcinoma (OSCC) cells is their ability to secrete different sized extracellular vesicles (EVs)— fluid-filled sacs containing a variety of cellular constituents. When EVs comprise of EGFR they are referred to as EGFR-EVs. Another feature of OSCC cells is their ability to undergo an epithelial to mesenchymal transition (EMT), which gives these cells the enhanced mobility that cancer cells require to migrate and invade healthy tissues. Here, Assistant Professor Takanori Eguchi and colleagues report on their study to understand the effects of cetuximab on all these features of OSCC when induced by EGF.

The researchers first looked at effects of cetuximab on EGF-driven EMT in OSCC cells by analyzing markers of EMT. Their results showed that while EGF binding resulted in EMT initiation, only a partial suppression of EMT was observed after cetuximab treatment. Next, the effects of EGF and cetuximab on the secretion of EGFR-EVs were investigated. Using sophisticated microscopy techniques, the team studied the structure and components of the EVs. While EGF increased this secretion, cetuximab did not reduce it even partially but rather promoted EGFR-EV secretion. In fact, high levels of secreted EFG-EVs were seen when co-stimulation with EGF and cetuximab carried out. If EGFR levels are increased in the vesicles, it makes sense that they are found in smaller amounts inside the cell, suggesting that this is a method by which cells clear excess EGFR out.
Based on this interpretation of their findings, the researchers then studied if the secreted EGFR-EVs contained cetuximab. Indeed, Western blot analysis of carefully prepared EVs revealed the presence of cetuximab, suggesting the possible mechanism by which OSCC cells get rid of cetuximab and develop resistance to its effects. Lastly, to check that genetic alterations in the cell line used were not responsible for the results the researchers investigated the panel of genes present but did not find any major aberrations.

The researchers conclude that “OSCC derived EVs trigger the secretion of a molecularly targeted antibody drug cetuximab, whose secretion could be a novel mechanism underlying antibody drug resistance in OSCC”\(^1\). Preventing this secretion might be a promising strategy in reducing cetuximab resistance, thereby increasing its effectiveness against HNSCC.

**Background**

**Receptors, effectors, and antibodies**

Receptors, such as EGFR, are proteins found on the cell surface or inside the cell. Receptors are usually activated when ligands such as proteins and chemicals bind to them. Upon activation, a chemical change usually ensues, followed by a cellular response. For example, when EGF binds EGFR, it results in dimerization of EGFR, followed by activation of signals inside the cell that are ultimately responsible for the cancer cell proliferation.

Antibodies are proteins usually produced in the plasma of organisms in response to foreign pathogens or antigens. Antibodies can neutralize pathogens by recognizing and binding to specific proteins on the pathogen. An extension of this concept is used in the production of monoclonal antibodies such as cetuximab. Monoclonal antibodies against a specific protein are usually produced and derived from animals. In this case, EGFR was the protein used to generate cetuximab, the antibody that can bind and neutralize it. Monoclonal antibodies are highly specific in nature.

**Squamous cells and epithelial to mesenchymal transition (EMT)**

Squamous cells are flat cells found primarily in the outer layer of the skin and some inner linings such as in the tongue, oral mucosa, and throat. Squamous cells can be classified as epithelial cells, the epithelium being the layer that forms the surface of the body. EMT is a cellular phenomenon by which epithelial cells switch to the shape and characteristic of mesenchymal cells; those that can be transformed into a variety of different cells. EMT is therefore a process that pre-cancer cells such as in OSCC cells undergo, to migrate and attack non-cancerous cells.
Caption
When EGF attaches to EGFR in OSCC cells, secretion of EGFR-EV and activation of EMT (illustrated as red diamonds), are seen (left). However, the effects of cetuximab on EGF-driven cells led to increased EGFR-EVs, which also contained cetuximab (Cmab-EGFR-EV), along with a partial suppression of EMT (right).

Reference
https://doi.org/10.1016/j.bbrc.2018.07.035

Reference (Okayama Univ. e-Bulletin): Assistant Professor Eguchi’s team
OU-MRU Vol.51 : Potential of 3D nanoenvironments for experimental cancer
PRESS RELEASE(February 2018) : The Production of Organoids with Cancer Stem-like Models Leads to a Successful Living Organism Analysis. Discovery of Organoids with Cancer Cells Efficiently Accumulating and Secreting Protein
PRESS RELEASE(May 2018) : Successful inhibition of cancer invasion and metastasis by targeting the PEX isoform / MMP3
PRESS RELEASE(May 2018) : Discovery and targeting of cancer progression factors from exosomes secreted by oral cancer cells
Correspondence to
Assistant Professor Takanori Eguchi, D.D.S., Ph.D.
Department of Dental Pharmacology,
Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Shikata-cho 2-5-1, Okayama city, Okayama 700-8558, Japan
E-mail: eguchi@okayama-u.ac.jp
https://scholar.google.com/citations?hl=en&user=d37h9nQAAAAJ&view_op=list_works&sortby=pubdate

Further information
Okayama University
1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: www-adm@adm.okayama-u.ac.jp
Website: http://www.okayama-u.ac.jp/index_e.html
Okayama Univ. e-Bulletin: http://www.okayama-u.ac.jp/user/kouhou/ebulletin/
About Okayama University (YouTube):
https://www.youtube.com/watch?v=iDL1coqPRYI
Okayama University Image Movie (YouTube):
https://www.youtube.com/watch?v=KU3hOIXS5kk

Okayama University Medical Research Updates (OU-MRU)
Vol.1 : Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testing
Vol.2 : Ensuring a cool recovery from cardiac arrest
Vol.3 : Organ regeneration research leaps forward
Vol.4 : Cardiac mechanosensitive integrator
Vol.5 : Cell injections get to the heart of congenital defects
Vol.6 : Fourth key molecule identified in bone development
Vol.7 : Anticancer virus solution provides an alternative to surgery
Vol.8 : Light-responsive dye stimulates sight in genetically blind patients
Vol.9 : Diabetes drug helps towards immunity against cancer
Vol.10 : Enzyme-inhibitors treat drug-resistant epilepsy
Vol.11 : Compound-protein combination shows promise for arthritis treatment
Vol.12 : Molecular features of the circadian clock system in fruit flies
Vol.13 : Peptide directs artificial tissue growth
Vol.14 : Simplified boron compound may treat brain tumours
Vol.15 : Metamaterial absorbers for infrared inspection technologies
Vol.16 : Epigenetics research traces how crickets restore lost limbs
Vol.17 : Cell research shows pathway for suppressing hepatitis B virus
Vol.18 : Therapeutic protein targets liver disease
Vol.19: Study links signalling protein to osteoarthritis
Vol.20: Lack of enzyme promotes fatty liver disease in thin patients
Vol.21: Combined gene transduction and light therapy targets gastric cancer
Vol.22: Medical supportive device for hemodialysis catheter puncture
Vol.23: Development of low cost oral inactivated vaccines for dysentery
Vol.24: Sticky molecules to tackle obesity and diabetes
Vol.25: Self-administered aroma foot massage may reduce symptoms of anxiety
Vol.26: Protein for preventing heart failure
Vol.27: Keeping cells in shape to fight sepsis
Vol.28: Viral-based therapy for bone cancer
Vol.29: Photoreactive compound allows protein synthesis control with light
Vol.30: Cancer stem cells’ role in tumor growth revealed
Vol.31: Prevention of RNA virus replication
Vol.32: Enzyme target for slowing bladder cancer invasion
Vol.33: Attacking tumors from the inside
Vol.34: Novel mouse model for studying pancreatic cancer
Vol.35: Potential cause of Lafora disease revealed
Vol.36: Overloading of protein localization triggers cellular defects
Vol.37: Protein dosage compensation mechanism unravelled
Vol.38: Bioengineered tooth restoration in a large mammal
Vol.39: Successful test of retinal prosthesis implanted in rats
Vol.40: Antibodies prolong seizure latency in epileptic mice
Vol.41: Inorganic biomaterials for soft-tissue adhesion
Vol.42: Potential drug for treating chronic pain with few side effects
Vol.43: Potential origin of cancer-associated cells revealed
Vol.44: Protection from plant extracts
Vol.45: Link between biological-clock disturbance and brain dysfunction uncovered
Vol.46: New method for suppressing lung cancer oncogene
Vol.47: Candidate genes for eye misalignment identified
Vol.48: Nanotechnology-based approach to cancer virotherapy
Vol.49: Cell membrane as material for bone formation
Vol.50: Iron removal as a potential cancer therapy
Vol.51: Potential of 3D nanoenvironments for experimental cancer
Vol.52: A protein found on the surface of cells plays an integral role in tumor growth and sustenance
Vol.53: Successful implantation and testing of retinal prosthesis in monkey eyes with retinal degeneration
Vol.54: Measuring ion concentration in solutions for clinical and environmental research
Vol.55: Diabetic kidney disease: new biomarkers improve the prediction of the renal prognosis
Vol.56: New device for assisting accurate hemodialysis catheter placement
Vol.57: Possible link between excess chewing muscle activity and dental disease

Okayama University supports the Sustainable Development Goals
About Okayama University

Okayama University is one of the largest comprehensive universities in Japan with roots going back to the Medical Training Place sponsored by the Lord of Okayama and established in 1870. Now with 1,300 faculty and 13,000 students, the University offers courses in specialties ranging from medicine and pharmacy to humanities and physical sciences.

Okayama University is located in the heart of Japan approximately 3 hours west of Tokyo by Shinkansen.

Website: [http://www.okayama-u.ac.jp/index_e.html](http://www.okayama-u.ac.jp/index_e.html)

Hirofumi Makino, M.D., Ph.D.
President, Okayama University

“Okayama University supports the Sustainable Development Goals”

---

Image: Map of Japan showing various cities and airports, with markers for Misasa Campus, Shikata Campus, Hisatsuyama Campus, and Hiraizumi Campus. A QR code is also present.